Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have been assigned a consensus rating of “Buy” from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $11.00.

Several research analysts recently commented on AQST shares. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a report on Friday, December 20th. JMP Securities restated a “market outperform” rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. Cantor Fitzgerald started coverage on Aquestive Therapeutics in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 target price on the stock. Finally, Leerink Partners increased their price target on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research report on Friday, October 25th.

Aquestive Therapeutics Price Performance

Shares of Aquestive Therapeutics stock opened at $3.05 on Wednesday. The firm has a market cap of $278.09 million, a price-to-earnings ratio of -6.78 and a beta of 2.71. The stock’s 50-day moving average is $4.09 and its 200-day moving average is $4.17. Aquestive Therapeutics has a one year low of $2.24 and a one year high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The business had revenue of $13.54 million during the quarter, compared to analysts’ expectations of $12.69 million. During the same quarter last year, the firm earned ($0.03) EPS. On average, equities analysts expect that Aquestive Therapeutics will post -0.47 EPS for the current year.

Hedge Funds Weigh In On Aquestive Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of AQST. Victory Capital Management Inc. bought a new stake in Aquestive Therapeutics in the second quarter valued at approximately $27,000. nVerses Capital LLC bought a new stake in Aquestive Therapeutics in the 3rd quarter valued at $28,000. The Manufacturers Life Insurance Company acquired a new stake in Aquestive Therapeutics during the 2nd quarter valued at $76,000. Harvey Capital Management Inc. bought a new position in Aquestive Therapeutics during the third quarter worth $88,000. Finally, Intech Investment Management LLC acquired a new position in shares of Aquestive Therapeutics in the third quarter valued at $90,000. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.